Optibrium, a leading developer of software and AI solutions for molecular design today announced the publication of a peer-reviewed study in Journal of Computer-Aided Molecular Design, ‘From UK-2A to florylpicoxamid: Active learning to identify a mimic of a macrocyclic natural product’
Nanobiotix partners with Janssen to commercialise radioenhancer oncology drug – Pharmaceutical Technology
While Nanobiotix would maintain operational control over the ongoing clinical studies, including NANORAY-312, Janssen would reserve the right to assume control of these studies. Image
July 10, 2023